Driving Breakthroughs in Healthcare, One Bold Idea at a Time

Featured

13 January 2026

Enspire DBS Therapy Announces $10.3 Million Series B1 Financing to Advance Pivotal Development of DBS-Enabled Stroke Rehabilitation

CLEVELAND, Jan. 13, 2026 /PRNewswire/ -- Enspire DBS Therapy, Inc. ("Enspire"), a clinical-stage company developing an implantable neuromodulation therapy for post-stroke recovery, today announced that it has raised $10.3 million in a Series B1 financing led by new investor Genesys Capital, with participation from existing investors Cleveland Clinic and JobsOhio Ventures.

Latest

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

11 December 2025

Antegrade Medical Announces the Closing of a $7.3M Seed Financing

28 October 2025

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

07 August 2025

All Articles

04 November 2024

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025

31 October 2024

Feldan Therapeutics announces the treatment of the first patient in the phase 1/2a clinical trial of its candidate fld-103, against Basal Cell Carcinoma

30 October 2024

Kapoose Creek Bio Acquires Exclusive License to Adapsyn Bioscience’s World-Leading AI Technology for Drug Development

20 September 2024

Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed

04 September 2024

Feldan Therapeutics Completes a US$ 21 Million Series B financing co-led by Genesys Capital and Fonds de Solidarité Ftq

24 June 2024